OR WAIT null SECS
inVentiv Health Clinical and Advaxis, Inc. announced they have entered into a global master services agreement...
inVentiv Health Clinical, a leading global clinical research organization (CRO), and Advaxis, Inc., a biotechnology company developing cancer immunotherapies, announced they have entered into a global master services agreement for the clinical development of certain immunotherapy product candidates in Advaxis's proprietary pipeline.
inVentiv initially will work with Advaxis to develop clinical study protocols and will serve as the CRO on the planned registrational trials that will evaluate the safety and efficacy of Advaxis' lead immunotherapy for cervical cancer, ADXS-HPV. In addition, inVentiv will provide feasibility and study start-up activities for the planned clinical development of ADXS-cHER2 in pediatric osteosarcoma.
Advaxis chose inVentiv Clinical because of its comprehensive, global clinical capabilities that offers medical and operational expertise, flexible services, commercial insight and a shared commitment to patients.
Read the full release here.